Medications for Ankylosing Spondylitis

11 results

  • acthar

    (Repository Corticotropin)
    Mallinckrodt ARD LLC
    Acthar Gel is indicated for treating infantile spasms in infants under 2, acute exacerbations of multiple sclerosis in adults, and as adjunctive therapy for various rheumatic disorders. It is also used for certain collagen diseases, severe dermatologic and allergic conditions, ophthalmic inflammatory diseases, symptomatic sarcoidosis, and nephrotic syndrome.

  • celebrex

    (Celecoxib)
    PFIZER LABORATORIES DIV PFIZER INC
    CELEBREX is indicated for managing signs and symptoms of osteoarthritis, rheumatoid arthritis, juvenile rheumatoid arthritis (in patients aged 2 and older), ankylosing spondylitis, acute pain in adults, and primary dysmenorrhea.

  • cimzia

    (certolizumab pegol)
    UCB, Inc.
    CIMZIA is indicated for treating moderate to severe Crohn's disease, rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, and moderate-to-severe plaque psoriasis in adults and eligible pediatric patients aged 2 years and older.

  • cyltezo

    (adalimumab-adbm)
    Boehringer Ingelheim Pharmaceuticals, Inc.
    CYLTEZO is indicated for treating moderately to severely active rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, chronic plaque psoriasis, hidradenitis suppurativa, and non-infectious uveitis in adults and pediatric patients aged 2 and older.

  • enbrel

    (etanercept)
    Immunex Corporation
    Enbrel is indicated for reducing symptoms and structural damage in rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, chronic moderate to severe plaque psoriasis, and active juvenile psoriatic arthritis in patients 2 years and older. It may be used alone or with methotrexate.

  • hulio

    (adalimumab-fkjp)
    Mylan Specialty L.P.
    HULIO is indicated for reducing signs and symptoms, and improving function in rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, chronic plaque psoriasis, hidradenitis suppurativa, and non-infectious uveitis in adults and children over 2 years.

  • inflectra

    (infliximab-dyyb)
    Pfizer Laboratories Div Pfizer Inc
    INFLECTRA is indicated for treating moderately to severely active Crohn's disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and plaque psoriasis in adults and pediatric patients aged 6 and older, particularly in cases unresponsive to conventional therapies.

  • rayos

    (prednisone)
    Horizon Therapeutics USA, Inc.
    RAYOS is indicated for severe allergic conditions, various dermatologic and endocrine diseases, gastrointestinal disorders (like Crohn's and ulcerative colitis), hematologic issues, neoplasms, nervous system conditions (such as multiple sclerosis), certain ophthalmic diseases, organ transplant rejection, pulmonary disorders, renal conditions, rheumatologic ailments, and specific infectious diseases.

  • simponi

    (golimumab)
    Janssen Biotech, Inc.
    SIMPONI is indicated for the treatment of adults with moderately to severely active rheumatoid arthritis (with methotrexate), active psoriatic arthritis (alone or with methotrexate), active ankylosing spondylitis, and moderately to severely active ulcerative colitis in patients with corticosteroid dependence or inadequate response to previous therapies.

  • taltz

    (ixekizumab)
    Eli Lilly and Company
    TALTZ is indicated for the treatment of moderate-to-severe plaque psoriasis in patients aged 6 and older, as well as for adults with active psoriatic arthritis, ankylosing spondylitis, and active non-radiographic axial spondyloarthritis with objective signs of inflammation.